CHUV (Centre Hospitalier Universitaire Vaudois)
↗Lausanne, Switzerland
The Lausanne University Hospital (CHUV) is one of the five university hospitals in Switzerland and a global hub for translational medical research. It serves as a primary healthcare provider for the Canton of Vaud while maintaining a dual role as a major academic institution in partnership with the University of Lausanne (UNIL) and the Swiss Federal Institute of Technology Lausanne (EPFL). The institution is particularly renowned for its work in oncology, immunology, and neurosciences.
CHUV's research ecosystem is bolstered by the Ludwig Institute for Cancer Research (Lausanne Branch), with which it shares a long-term strategic partnership. The hospital houses a dedicated Center for Experimental Therapeutics (CTE) and advanced GMP manufacturing facilities for cell and gene therapies. Through its technology transfer office (recently rebranded as Knowledge Transfer UNIL CHUV), it actively commercializes academic discoveries, leading to high-profile spin-offs in the biotechnology and medical device sectors.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Biotechnology
Sub-Industry:Oncology & Cell Therapy Research
SIZE & FINANCIALS
Employees:10000+
Revenue:$2.3B
Founded:1890
Ownership:government
Status:operating
FUNDING
Stage:Pre-IPO
Total Raised:$2.3B
Investors:Canton of Vaud, Swiss National Science Foundation (SNSF), InnoSuisse, European Research Council (ERC)
PIPELINE
Stage:Phase 3
Lead Drug Stage:Phase 3
Modalities:Cell therapy, Gene therapy, mAb, Small molecule, RNA, Neuroprosthetics, Cancer vaccines
Active Trials:240
Trial Phases:Phase 1: 85 | Phase 2: 110 | Phase 3: 35 | Phase 4: 10
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Parent Company:Canton of Vaud
Subsidiaries:Unisanté (University Center for General Medicine and Public Health), Knowledge Transfer UNIL CHUV (TTO)
Key Partnerships:Ludwig Institute for Cancer Research (Strategic oncology research partnership), University of Lausanne (UNIL) (Academic and faculty partnership), EPFL (Medical engineering and neurotech collaborations), Pfizer (Clinical trials in breast cancer), Jazz Pharmaceuticals (ACTION Study collaborator), CERN (FLASH radiotherapy development)
COMPETITION
Position:Leader
Competitors:HUG (Hôpitaux Universitaires de Genève), University Hospital Basel (USB), University Hospital Zurich (USZ), Inselspital (University Hospital of Bern)
LEADERSHIP
Key Executives:
Claire Charmet - General Director
Matthias Roth-Kleiner - Medical Director
George Coukos - Head of Oncology Department
Board Members:Reto Meuli (President of the Strategic Council), Philippe Milliet (Member (Pharmacist & Independent Administrator))
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with CHUV (Centre Hospitalier Universitaire Vaudois). The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.